Ascites of patients with solid tumors shows distinct inflammatory patterns

Julia M. Berger; Martin Korpan; Carina Zierfuss; Katharina Syböck; Erwin Tomasich; Andreas Kienzle; Maria Koenig; Markus Kleinberger; Lynn Gottmann; Birgit Fendl; Cihan Ay; Johannes Pammer; Catharina Müller; Rudolf Oehler; Lorenz Balcar; Thomas Reiberger; Elisabeth S. Bergen; Barbara Niederdorfer; Matthias Preusser; Anna S. Berghoff

doi:10.1002/cac2.70031

Cancer Communications ›› 2025, Vol. 45 ›› Issue (8) :936 -940. DOI: 10.1002/cac2.70031

LETTER TO THE JOURNAL

Ascites of patients with solid tumors shows distinct inflammatory patterns

Author information +

History +

PDF

Cite this article

Download citation ▾

Julia M. Berger, Martin Korpan, Carina Zierfuss, Katharina Syböck, Erwin Tomasich, Andreas Kienzle, Maria Koenig, Markus Kleinberger, Lynn Gottmann, Birgit Fendl, Cihan Ay, Johannes Pammer, Catharina Müller, Rudolf Oehler, Lorenz Balcar, Thomas Reiberger, Elisabeth S. Bergen, Barbara Niederdorfer, Matthias Preusser, Anna S. Berghoff. Ascites of patients with solid tumors shows distinct inflammatory patterns. Cancer Communications, 2025, 45(8): 936-940 DOI:10.1002/cac2.70031

登录浏览全文

4963

注册一个新账户忘记密码

References

Publishing order | Descend order by publishing year | Descend order by cited within

[1]	Berger JM, Preusser M, Berghoff AS, Bergen ES. Malignant ascites: Current therapy options and treatment prospects. Cancer Treat Rev. 2023; 121: 102646.

[2]	Berger JM, Alany A, Puhr R, Berchtold L, Friedrich A, Scheiner B, et al. Clinical risk factors for ascites in metastatic pancreatic cancer. ESMO Open. 2023; 8(2): 101200.

[3]	Zhang Y, Qian L, Chen K, Gu S, Wang J, Meng Z, et al. Intraperitoneal oncolytic virotherapy for patients with malignant ascites: Characterization of clinical efficacy and antitumor immune response. Molecular Therapy - Oncolytics. 2022; 25: 31–42.

[4]	Sartori S, Nielsen I, Tassinari D, Trevisani L, Abbasciano V, Malacarne P. Evaluation of a Standardized Protocol of Intracavitary Recombinant Interferon Alpha-2b in the Palliative Treatment of Malignant Peritoneal Effusions: A Prospective Pilot Study. Oncology. 2001; 61(3): 192–6.

[5]	Jordan K, Luetkens T, Gog C, Killing B, Arnold D, Hinke A, et al. Intraperitoneal bevacizumab for control of malignant ascites due to advanced-stage gastrointestinal cancers: A multicentre double-blind, placebo-controlled phase II study – AIO SUP-0108. European Journal of Cancer. 2016; 63: 127–34.

[6]	Sjoquist KM, Espinoza D, Mileshkin L, Ananda S, Shannon C, Yip S, et al. REZOLVE (ANZGOG-1101): A phase 2 trial of intraperitoneal bevacizumab to treat symptomatic ascites in patients with chemotherapy-resistant, epithelial ovarian cancer. Gynecologic Oncology. 2021; 161(2): 374-81.

[7]	Kudo T, Murai Y, Kojima Y, Uehara K, Satoh T. Efficacy and safety of tolvaptan in patients with malignant ascites: a phase 2, multicenter, open-label, dose-escalation study. Japanese Journal of Clinical Oncology. 2021; 51(3): 354–62.

[8]	Teschendorff AE, Breeze CE, Zheng SC, Beck S. A comparison of reference-based algorithms for correcting cell-type heterogeneity in Epigenome-Wide Association Studies. BMC Bioinformatics. 2017; 18(1): 105.

[9]	Yang Y, Jun L, Chao J, Yuhao Z, Zhigang B, Yingchi Y, et al. Inhibition of neuroactive ligand–receptor interaction pathway can enhance immunotherapy response in colon cancer: an in silico study. Expert Review of Anticancer Therapy. 2023; 23(11): 1205–15.